Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ragweed Allergy Clear all
Terminated Phase 2 Interventional

Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

NCT00387738
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate, Histamine base
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Oxford, Alabama • Stockbridge, Georgia • Normal, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jun 26, 2026, 4:27 AM EDT
Terminated Phase 1 Interventional

Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections

NCT03038971
View directory record Official record
Conditions
Allergic Conjunctivitis, Allergic Rhinitis
Interventions
Dose Level 1, Dose Level 2, Placebo
Biological
Lead sponsor
Woodmont Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety/Tolerability of Ragweed MATA MPL

NCT00423787
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
Ragweed MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 59 Years
Enrollment
993 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
59
States / cities
Waterbury, Connecticut • Atlanta, Georgia • Conyers, Georgia + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2010 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber

NCT01222299
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
bepotastine besilate nasal product - low dose, bepotastine besilate nasal product - medium dose, bepotastine besilate nasal product - high dose, placebo comparator nasal product
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Phase 3 Interventional

Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action

NCT00118729
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
GW685698X Aqueous Nasal Spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Woodstock, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*

NCT01240889
View directory record Official record
Conditions
Allergy
Interventions
Fluticasone, Fluticason
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

DNA Vaccine for Ragweed Allergic Adults

NCT00346086
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
AIC (Amb a 1 Immunostimulatory Conjugate)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Jun 26, 2026, 4:27 AM EDT
Completed No phase listed Observational

Examining the Link Between Depression and Seasonal Allergies

NCT00770068
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of AL-53817 Nasal Spray Solution

NCT01454505
View directory record Official record
Conditions
Nasal Allergies, Allergies
Interventions
AL-53817 nasal spray solution, Vehicle nasal spray
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

NCT00258635
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
RagweedMATAMPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Novi, Michigan • Minneapolis, Minnesota • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jun 26, 2026, 4:27 AM EDT
Completed No phase listed Observational

Ragweed Observational Study

NCT01398137
View directory record Official record
Conditions
Ragweed Allergy
Interventions
Not listed
Lead sponsor
Circassia Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Owensboro, Kentucky • Minneapolis, Minnesota • Plymouth, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Jun 26, 2026, 4:27 AM EDT
Completed No phase listed Observational

A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season

NCT00982163
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2009 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

NCT00078195
View directory record Official record
Conditions
Hay Fever, Hypersensitivity, Allergy, Rhinitis
Interventions
omalizumab, Placebo omalizumab, Ragweed rush immunotherapy (RIT), Placebo rush immunotherapy (RIT), Ragweed immunotherapy (IT), Placebo immunotherapy (IT)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Iowa City, Iowa • Omaha, Nebraska • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

NCT00929968
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, VAK694, Fluticasone
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jun 26, 2026, 4:27 AM EDT
Terminated No phase listed Observational

Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America

NCT02601690
View directory record Official record
Conditions
Allergy
Interventions
Blood Sampling
Other
Lead sponsor
Adiga Life Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Upland, California • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jun 26, 2026, 4:27 AM EDT
Terminated Phase 2 Interventional

Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug

NCT00318747
View directory record Official record
Conditions
Asthma, Allergy, Allergic Rhinitis, Rhinitis, Allergic, Seasonal
Interventions
Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Baltimore, Maryland • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies

NCT00599872
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Standardized Ragweed Allergenic Extract, Placebo
Biological
Lead sponsor
Greer Laboratories
Industry
Eligibility
18 Years to 50 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
30
States / cities
Normal, Illinois • Evansville, Indiana • Iowa City, Iowa + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Jun 26, 2026, 4:27 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy

NCT02676765
View directory record Official record
Conditions
Immunologic Desensitization
Interventions
allergen extract tablet, Placebo tablet
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy

NCT01353079
View directory record Official record
Conditions
Allergy
Interventions
Short Ragweed Pollen Allergenic Extract, Placebo
Biological
Lead sponsor
Greer Laboratories
Industry
Eligibility
18 Years to 55 Years
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Warrenton, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Safety of ALK Ragweed Tablet

NCT00330083
View directory record Official record
Conditions
Allergy
Interventions
ALK Ragweed Tablet
Biological
Lead sponsor
ALK-Abelló A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2007 · Synced Jun 26, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Results available

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

NCT00502775
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
fluticasone furoate, fexofenadine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
42
States / cities
Little Rock, Arkansas • Albany, Georgia • Columbus, Georgia + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Jun 26, 2026, 4:27 AM EDT